# Alector (ALEC) — News

ALEC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alec/news

## Recent headlines

- [Alector, Inc.: H.C. Wainwright raises target price to $8 from $5](https://www.ainvest.com/news/alector-wainwright-raises-target-price-8-5-2610) — AInvest Wire, Oct 14, 2026
  H.C. Wainwright has raised its price target for Alector, Inc. (NASDAQ: ALEC) to $8 from $5, reflecting a revised outlook on the company’s valuation and potential for future growth. This adjustment comes amid a broader reassessment of Alector’s business trajectory following recent clinical setbacks…
- [Alector Inc: Morgan Stanley raises target price to $3.00 from $2.00](https://www.ainvest.com/news/alector-morgan-stanley-raises-target-price-3-00-2-00-2610) — AInvest Wire, Oct 6, 2026
  Morgan Stanley has raised its price target for Alector Inc (NASDAQ: ALEC) to $3.00 from $2.00, maintaining an "Underweight" rating on the stock. The adjustment follows recent developments, including the company’s strategic shift to focus on its Alector Brain Carrier (ABC) platform for…
- [Alector shares jump 21.5% to $2.19 after Roche inks up to $1.27 bln licensing agreement for co's Parkinson's therapy](https://www.ainvest.com/news/alector-shares-jump-21-5-2-19-roche-inks-1-27-bln-licensing-agreement-parkinson-therapy-2610) — AInvest Wire, Oct 5, 2026
  Alector Inc. (ALTR) shares rose 21.5% to $2.19 on Thursday following the announcement of a licensing agreement with Roche Holding AG for the development of Alector’s experimental Parkinson’s disease therapy, AL001 [1]. Under the terms of the deal, Roche will pay Alector up to $1.27 billion,…
- [Alector shares jump 77.4% to $3.21 premarket after Roche inks up to $1.27 bln licensing agreement for co's Parkinson's therapy](https://www.ainvest.com/news/alector-shares-jump-77-4-3-21-premarket-roche-inks-1-27-bln-licensing-agreement-parkinson-therapy-2610) — AInvest Wire, Oct 5, 2026
  Alector Inc. (ALEC) shares surged 77.4% to $3.21 in premarket trading following the announcement of a licensing agreement with Roche for its Parkinson’s disease therapy. The deal, valued up to $1.27 billion, includes upfront payments and potential milestone-based incentives, reflecting strong…
- [Alector eligible for up to $1.17B in milestone payments](https://www.ainvest.com/news/alector-eligible-1-17b-milestone-payments-2610) — AInvest Wire, Oct 5, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).